Linzess side effects and hair loss is a concern raised by patients taking linaclotide, known in the UK and EU as Constella. Linaclotide is a prescription-only guanylate cyclase-C receptor agonist licensed for irritable bowel syndrome with constipation (IBS-C) in adults. Whilst its most recognised side effects are gastrointestinal — including diarrhoea, bloating, and abdominal pain — some patients report hair shedding and wonder whether their medication is responsible. This article explains what the UK clinical evidence says, when to seek medical advice, and what alternatives are available on the NHS.

What Is Linzess and How Is It Used in the UK?

Linzess (linaclotide) is available in the UK as Constella, licensed for IBS with constipation in adults and prescribed at 290 micrograms once daily, at least 30 minutes before the first meal, per NICE TA318.

Not sure if this is normal? Chat with one of our pharmacists →

Linzess is a brand name for linaclotide, a prescription medication used in the United States. In the UK and across the EU, the same active ingredient is licensed and marketed under the brand name Constella.^[1] Patients researching 'Linzess' should be aware that Constella is the equivalent product available through the NHS and via private prescription in the UK.

In the UK, linaclotide (Constella) is licensed for adults only for the treatment of irritable bowel syndrome with constipation (IBS-C). It is not licensed in the UK or EU for chronic idiopathic constipation (a separate condition), which is an important distinction from its US labelling.^[1][2]

Linaclotide works as a guanylate cyclase-C (GC-C) receptor agonist. When taken orally, it binds to receptors on the inner lining of the intestine, stimulating the production of cyclic guanosine monophosphate (cGMP). This increases fluid secretion into the intestinal lumen and accelerates bowel transit, helping to relieve constipation and associated abdominal discomfort. Importantly, linaclotide acts locally within the gut and is minimally absorbed into the bloodstream, which limits its systemic effects.^[1]

NICE guidance (TA318) recommends linaclotide for adults with moderate-to-severe IBS-C when other treatments — such as dietary changes, laxatives, and antispasmodics — have not provided adequate relief.^[2] It is prescribed at a dose of 290 micrograms once daily, taken at least 30 minutes before the first meal of the day. If treatment has not provided adequate benefit after 12 weeks, it should be stopped, in line with NICE TA318.

Important safety information from the UK Summary of Product Characteristics (SmPC):

• Linaclotide is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

• It must not be used in patients under 18 years of age.

• If you are pregnant, planning a pregnancy, or breastfeeding, discuss the risks and benefits with your GP or specialist before taking this medicine, as data in these groups are limited.

As with all prescription medicines, linaclotide should only be used under the supervision of a qualified healthcare professional.

Common and Reported Side Effects of Linaclotide

The most common side effects of linaclotide are gastrointestinal, including diarrhoea, abdominal pain, and bloating; hair loss is not a recognised adverse effect in the UK SmPC or EMA data.

Experiencing these side effects? Our pharmacists can help you navigate them →

Because linaclotide acts primarily within the gastrointestinal tract, the most frequently reported side effects are digestive in nature. According to the UK Summary of Product Characteristics (SmPC) for Constella and the European Medicines Agency (EMA) product information, the most common adverse effects include:

• Diarrhoea — the most frequently reported side effect, occurring in a significant proportion of users, and occasionally severe enough to require discontinuation

• Abdominal pain and discomfort

• Flatulence and bloating

• Abdominal distension

• Nausea

• Faecal urgency or incontinence (less commonly)

Diarrhoea can sometimes be severe and lead to dehydration, particularly in older adults or those with other health conditions. If you experience severe diarrhoea, you should stop taking linaclotide and seek prompt medical advice; ensure you remain well hydrated. This is in line with the UK SmPC. For milder diarrhoea, contact your GP for guidance before making any changes to your treatment.

Regarding hair loss specifically — alopecia is not listed as a recognised adverse effect of linaclotide in the UK SmPC for Constella or in the EMA EPAR, which includes data from clinical trials and post-marketing surveillance.^[1] There is no established pharmacological mechanism by which linaclotide, given its minimal systemic absorption, would be expected to cause hair thinning or alopecia.^[1] However, some patients do report hair loss in online forums and patient communities in association with taking the medication.

It is important to note that correlation does not imply causation. Hair loss is a common condition with many potential causes, including nutritional deficiencies (such as iron or vitamin D), thyroid dysfunction, stress, hormonal changes, and other medications. If a patient notices hair loss whilst taking linaclotide, there is no officially recognised link between the two, and other causes should be thoroughly investigated. Any such concerns should be discussed with a GP.

When to Speak to Your GP or Pharmacist

Stop linaclotide and seek prompt medical advice if you experience severe or persistent diarrhoea, blood in stools, or worsening abdominal pain; hair loss should be mentioned at your next GP appointment for investigation.

Whilst linaclotide is generally well tolerated, there are specific circumstances in which patients should seek prompt medical advice. Knowing when to contact a healthcare professional is an important part of safe medication use.

Stop taking linaclotide and seek medical advice promptly if you experience:

• Severe or persistent diarrhoea — stop the medication and contact your GP or seek urgent care; ensure you remain well hydrated

• Blood in your stools or a significant unexplained change in bowel habit

• Worsening abdominal pain rather than improvement

Seek emergency care immediately if you experience signs of a serious allergic reaction, including rash, swelling of the face, lips, tongue or throat, or difficulty breathing.

Additional important cautions:

• Linaclotide must not be taken by anyone under 18 years of age.^[1]

• It is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction — if you develop symptoms such as severe abdominal pain, vomiting, or inability to pass stools or wind, seek urgent medical attention.^[1]

• If you are pregnant, planning a pregnancy, or breastfeeding, speak to your GP or specialist before continuing treatment.

For milder side effects that are not severe, contact your GP or pharmacist before stopping treatment, as they can help you weigh the benefits and risks of continuing or switching to an alternative.

If you notice hair loss during your course of linaclotide, mention this to your GP at your next appointment. Your doctor may wish to carry out blood tests to rule out common underlying causes such as anaemia, thyroid disorders, or nutritional deficiencies — all of which can cause hair shedding and are likely unrelated to your medication.

The MHRA operates a Yellow Card scheme, which allows both patients and healthcare professionals to report suspected adverse drug reactions.^[4] If you believe linaclotide may be contributing to hair loss or any other unexpected symptom, you can submit a report at yellowcard.mhra.gov.uk, which helps build the national evidence base for drug safety.

Managing Side Effects and Alternatives Available on the NHS

Gastrointestinal side effects may be managed with consistent dosing and hydration; NHS alternatives for IBS-C include antispasmodics, osmotic laxatives, and dietary interventions, in line with NICE CG61 and TA318.

For patients who experience troublesome side effects from linaclotide, there are several practical strategies and alternative treatments that can be considered in discussion with a GP or gastroenterologist.

Managing gastrointestinal side effects:

• Taking linaclotide consistently at least 30 minutes before breakfast, as directed, can help with tolerability.

• If diarrhoea is a problem but not severe, your GP may suggest a temporary interruption of treatment followed by rehydration, before considering whether to restart — in line with the UK SmPC. There is no lower licensed dose of linaclotide available in the UK, so dose reduction is not an appropriate strategy.^[1]

• Staying well hydrated and maintaining a balanced diet rich in soluble fibre can support gut health alongside medication.

If hair loss is a concern, the priority is to identify and treat any underlying cause. Your GP may refer you to a dermatologist if hair loss is significant or unexplained. Common investigations include full blood count, ferritin, thyroid function tests, and vitamin D levels. Treating any identified deficiency often leads to improvement in hair health over time.

NHS alternatives for IBS-C (in line with NICE guideline CG61 and NICE TA318):

• Dietary and lifestyle interventions — increasing fluid intake, physical activity, and soluble dietary fibre remain cornerstones of long-term bowel health management and are recommended as first-line measures.

• Antispasmodics (e.g., mebeverine, hyoscine) — for abdominal pain and cramping associated with IBS.

• Osmotic laxatives such as macrogol (e.g., Movicol) — widely used and appropriate where constipation is the predominant symptom.

• Stimulant laxatives such as bisacodyl or senna — for short-term use where appropriate.

For adults with chronic constipation (a separate condition from IBS-C) where laxatives have not provided adequate relief, prucalopride (Resolor) — a selective serotonin (5-HT₄) receptor agonist — may be considered. Prucalopride is licensed for chronic constipation in adults and is available on the NHS; current NICE and BNF guidance should be consulted for up-to-date prescribing criteria, as recommendations have evolved since the original NICE TA211 appraisal.

If linaclotide is not suitable or is poorly tolerated, a gastroenterology referral may be appropriate to explore further options. Shared decision-making between patient and clinician is essential to finding the most effective and tolerable treatment plan.

Frequently Asked Questions